THERAPY FOR COMPLICATIONS OF DIABETES

A selective ET A receptor antagonist for use in a method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome is disclosed. A selective ET A receptor antagonist for use in treating a complex of comorbidities in an elderly...

Full description

Saved in:
Bibliographic Details
Main Authors GORCZYNSKI, RICHARD J, RODEN, ROBERT L, GERBER, MICHAEL J
Format Patent
LanguageEnglish
French
Published 03.01.2017
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:A selective ET A receptor antagonist for use in a method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome is disclosed. A selective ET A receptor antagonist for use in treating a complex of comorbidities in an elderly diabetic human subject, wherein the selective ET A receptor antagonist is for administration in combination or as adjunctive therapy with (a) at least one additional agent that is (i) other than a selective ET A receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension, and optionally (b) at least one antihypertensive other than a selective ET A receptor antagonist is disclosed. Further, a therapeutic combination comprising a selective ET A receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ET A receptor antagonist is disclosed.
Bibliography:Application Number: CA20082904447